In the rapidly evolving landscape of eye care, the EyeLinxโข Minimally Invasive Glaucoma Surgery (MIGS) Devices have emerged as true game-changers. In 2020, the MIGS market witnessed a significant leap, with EyeLinxโข leading the charge, generating an astonishing $298.75 million in revenue. However, this is just the beginning of our extraordinary journey.
With our unwavering commitment to innovation and patient well-being, we project that the EyeLinxโข MIGS Devices market will skyrocket to an unprecedented $5,099.38 million by 2030. This remarkable growth is driven by the fusion of cutting-edge technology and human-centric design, propelling the market at an incredible CAGR of 35.0% from 2021 to 2030.
๐๐จ๐ฐ๐ง๐ฅ๐จ๐๐ ๐๐๐ฆ๐ฉ๐ฅ๐ ๐๐๐ฉ๐จ๐ซ๐ญ: https://www.alliedmarketresearch.com/request-sample/4547
Key Market Players
ASICO LLC, NOVARTIS INTERNATIONAL AG (ALCON INC.), SANTEN PHARMACEUTICAL CO. LTD., ISTAR MEDICAL SA, CARL ZEISS MEDITEC AG, ABBVIE INC. (ALLERGAN), ZIEMER OPHTHALMIC SYSTEMS AG, GLAUKOS CORPORATION, LUMENIS LTD., IVANTIS INC.
โMinimally Invasive Glaucoma Surgery (MIGS) Devices Market Report Highlights
Market Segmentation:
- By Surgery:
a. Glaucoma in Conjunction with Cataract: This category includes MIGS procedures that are performed simultaneously with cataract surgery. As cataracts often occur alongside glaucoma, combining treatments can be beneficial in managing both conditions effectively.
b. Stand Alone Glaucoma: These are MIGS procedures performed independently to treat glaucoma when cataract surgery is not required. - By Target:
a. Trabecular Meshwork: The trabecular meshwork is a critical drainage structure in the eye responsible for regulating intraocular pressure. MIGS devices targeting this area aim to improve fluid outflow, reducing pressure on the optic nerve and slowing glaucoma progression.
b. Suprachoroidal Space: Devices designed to target the suprachoroidal space aim to enhance fluid drainage, providing an alternative pathway to reduce intraocular pressure.
c. Others: This category includes MIGS devices targeting other specific structures or pathways within the eye to manage glaucoma effectively. - By Product:
a. MIGS Stents: MIGS stents are tiny, biocompatible tubes or scaffolds implanted in the eye to create a pathway for fluid drainage, thereby reducing intraocular pressure.
b. MIGS Shunts: MIGS shunts are small devices that divert aqueous humor from the anterior chamber of the eye to a reservoir or drainage area, effectively lowering intraocular pressure.
c. OTHER (TRABECTOME/MICRO-IMPLANTS/MICRO-CATHETERS): This category includes various other innovative MIGS devices like trabectome, micro-implants, and micro-catheters, each designed to address glaucoma through unique mechanisms. - By End User:
a. Eye Hospitals: Specialized eye hospitals are key stakeholders in the MIGS market, providing advanced glaucoma care and conducting MIGS procedures for patients with various levels of glaucoma severity.
b. Ophthalmology Clinics: Ophthalmology clinics play a vital role in diagnosing and managing glaucoma. They may offer MIGS procedures as a part of their comprehensive glaucoma treatment options.
c. Outpatient Surgical Centers: Outpatient surgical centers cater to patients who require surgical interventions but do not need extended hospital stays. MIGS procedures performed in these centers can offer convenience and cost-effectiveness to patients.
๐๐ฎ๐ซ๐๐ก๐๐ฌ๐ ๐๐ซ๐๐ฆ๐ข๐ฎ๐ฆ ๐๐จ๐ฉ๐ฒ ๐จ๐ Minimally Invasive Glaucoma Surgery (MIGS) Devices Market ๐๐ซ๐จ๐ฐ๐ญ๐ก ๐๐๐ฉ๐จ๐ซ๐ญ ๐๐ญ: https://www.alliedmarketresearch.com/minimally-invasive-slaucoma-surgery-MIGS-devices-market/purchase-options